CN105832960A - Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome - Google Patents
Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome Download PDFInfo
- Publication number
- CN105832960A CN105832960A CN201610401817.9A CN201610401817A CN105832960A CN 105832960 A CN105832960 A CN 105832960A CN 201610401817 A CN201610401817 A CN 201610401817A CN 105832960 A CN105832960 A CN 105832960A
- Authority
- CN
- China
- Prior art keywords
- colla cornus
- cornus cervi
- fructus jujubae
- water
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of deer-horn glue particles in preparing a drug for treating perimenopausal syndrome, and the drug use problem in treating the perimenopausal syndrome can be effectively solved. A method is that the deer-horn glue particles are prepared from 18-22g of deer-horn glue, 9-11g of Chinese yam fried with earth and 9-11g of jujubes, wherein water with the weight being 6-8 times the weight of the jujubes is added into the jujubes each time for decoction, decoction is performed twice, 30-40 minutes every time; two decoction solutions obtained by twice decoction are combined, and the mixture is concentrated until the concentration of a crude drug is 2g/ml, so that water-decocted jujube concentrated liquor is obtained; the deer-horn glue is molten by heat and is dissolved into the water-decocted jujube concentrated liquor to obtain mixed liquor; the Chinese yam fried with the earth is crushed into fine powder which passes through a 100-mesh sieve, the fine powder is dissolved into the mixed liquor to obtain a mixture, the mixture is dried under reduced pressure, the dried mixture is crushed into fine powder which passes through the 100-mesh sieve, and the fine powder is uniformly pelletized by use of alcohol with mass concentration being 90%, and is dried. According to the application, the deer-horn glue particles are rich in raw materials, simple in preparation method, have the effect of remarkably increasing the uterus index, change the states of endometrium, glands and muscular layers, and can be effectively used for preparing the drug for treating the perimenopausal syndrome.
Description
Technical field
The present invention relates to medicine, a kind of Colla cornus cervi granule answering in preparation treatment perimenopausal syndrome medicine
With.
Background technology
The underlying cause that perimenopausal syndrome occurs is the ovary caused due to physiological or pathologic or operation
Nonfunction.Ovarian function once exhaustion or cut and destruction, the estrogen of ovarian secretion will reduce.Women whole body has
More than 400 kind of estrogen receptor, is distributed in the almost all of tissue of women whole body and organ, accepts control and the domination of estrogen,
Once estrogen decrease, will cause the degeneration of organ and tissue to change, a series of symptom occur.
In perimenopausal syndrome, most typical symptom is hectic fever, flushing.Multiple being born in 45～55 years old, most of women can
The symptom that weight does not waits occur, have people to have started in menopause transition symptom to occur, lasting till post menopausal 2～3 years, a few peoples can
Last till that post menopausal 5～10 years symptoms have alleviated or disappeared.Artificial menopause person i.e. may occur in which the most after surgery and encloses absolutely for 2 weeks
Menstrual period syndrome, reaches peak for postoperative 2 months, sustainable 2 years as long as.
1. change in menstrual cycle characteristics
Change in menstrual cycle is that climacteric clinical symptoms the earliest occurs, is divided into 3 types:
(1) menstrual cycle extends, and reduces through amount, last menopause.
(2) menstrual cycle is irregular, menostaxis, menorrhagia, even massive hemorrhage or hemorrhage dripping urine endlessly, the most gradually
Reduce and stop.
(3) menstruation stops suddenly, more rare.Due to ovary anovulation, estrogen level fluctuates, endometrium easily occurs
Cancer.For abnormal bleeding person, should row diagnostic curettage, eliminating is cancerated.
2. vasomotor symptoms
Clinical manifestation is hectic fever, perspiration, is the performance of vasomotoricity instability, is that perimenopausal syndrome is the most prominent
Characteristic symptom.Hectic fever rises from shirtfront, pours into incidence, then involves whole body, and minority women is limited to head, neck and breast
Room.Region patient at flushing feels scorching hot, skin rubefaction, and then explosive perspiration.Last for several seconds, to several minutes, is sent out
Working frequency every day for several times to 30～50 times.Night or stress state easily inspire.This kind of vascular function instability can last 1 year, has
Time as long as five years or longer.
Though the existing multi-medicament having treatment perimenopausal syndrome, but for various reasons, it uses and curative effect not to the utmost
People's will, therefore, the medicine developing new treatment perimenopausal syndrome is imperative.
Summary of the invention
For above-mentioned situation, for overcoming the defect of prior art, the purpose of the present invention is just to provide a kind of Colla cornus cervi granule
Application in preparation treatment perimenopausal syndrome medicine, can effectively solve the medicine for treatment problem of perimenopausal syndrome.
The technical scheme that the present invention solves is, this Colla cornus cervi granule is by Colla cornus cervi 18-22g, stir-baked RHIZOMA DIOSCOREAE with soil 9-11g, big
Fructus Jujubae 9-11g makes, and wherein, Fructus Jujubae, every time with the soak by water 2 times of Fructus Jujubae weight 6-8 times, decocts 30-40 minute every time, merges two
Secondary decocting liquid, is concentrated into and is equivalent to, containing crude drug 2g/ml, obtain Fructus Jujubae water drug-decocting concentrating liquid；After Colla cornus cervi molten, it is dissolved in Fructus Jujubae decocting dense
In contracting liquid, obtain mixed liquor；Stir-baked RHIZOMA DIOSCOREAE with soil was ground into the fine powder of 100 mesh sieves again, dissolved in mixed liquor, decompression drying, pulverize
Became the fine powder of 100 mesh sieves, and with the ethanol mixed pelletization of mass concentration 90%, dried, obtain Colla cornus cervi granule；
This Colla cornus cervi granule is effective to preparation treatment perimenopausal syndrome, it is achieved Colla cornus cervi granule encloses in preparation treatment
Application in menopausal syndrome medicine.
Abundant raw material of the present invention, preparation method is simple, has the effect significantly improving uterus index, change endometrium,
Body of gland, the state of muscle layer, can be effectively used for preparation treatment perimenopausal syndrome medicine, has opened up the new use of Colla cornus cervi granule
On the way.
Detailed description of the invention
Below in conjunction with concrete condition and embodiment, the detailed description of the invention of the present invention is elaborated.
Embodiment 1
The present invention is in being embodied as, and described Colla cornus cervi granule is by Colla cornus cervi 20g, stir-baked RHIZOMA DIOSCOREAE with soil 10g, Fructus Jujubae 10g
Make, wherein, Fructus Jujubae boiling 2 times, add the water of Fructus Jujubae weight 8 times for the first time, decoct 40 minutes, filter, obtain for the first time
Filtrate, medicinal residues, again with the water of Fructus Jujubae weight 6 times, decoct 30 minutes, filter, and obtain second time filtrate, merge twice filtrate, be concentrated into
Be equivalent to, containing crude drug 2g/ml, obtain Fructus Jujubae water drug-decocting concentrating liquid；After Colla cornus cervi molten, it is dissolved in Fructus Jujubae water drug-decocting concentrating liquid, obtains mixing
Liquid；Stir-baked RHIZOMA DIOSCOREAE with soil was ground into the fine powder of 100 mesh sieves again, dissolved in mixed liquor, decompression drying, it was ground into 100 mesh sieves
Fine powder, with the ethanol mixed pelletization of mass concentration 90%, dries, obtains Colla cornus cervi granule.
Embodiment 2
The present invention is in being embodied as, and described Colla cornus cervi granule is by Colla cornus cervi 19g, stir-baked RHIZOMA DIOSCOREAE with soil 10.5g, Fructus Jujubae
9.5g makes, and preparation method is with embodiment 1.
Embodiment 3
The present invention is in being embodied as, and described Colla cornus cervi granule is by Colla cornus cervi 21g, stir-baked RHIZOMA DIOSCOREAE with soil 9.5g, Fructus Jujubae
10.5g makes, and preparation method is with embodiment 1.
In said medicine, wherein Colla cornus cervi temperature compensation Liver and kidney, benefit intensive culture blood, dizzy for blood deficiency, waist knee joint acid is cold, and asthenia disappears
Thin.
Rhizoma Dioscoreae is RHIIZOMA DIOSCOREAE fr0m Henan of China, has nourishing strong, aid digestion, holds back sweating due to debility, and effect of antidiarrheal cures mainly insufficiency of the spleen diarrhoea, the deficiency of the lung
Cough, diabetes are quenched one's thirst, oliguria frequency, seminal emission, women's leukorrhagia and dyspeptic chronic enteritis.
Fructus Jujubae is warm in nature, sweet in the mouth, has vigorate qi and replenish the blood, invigorating the spleen and regulating the stomach, wind effect.
The efficient combination of said medicine, supports mutually, and has the effect improving uterus index through science preparation, changes son
Endometrium, body of gland, the state of muscle layer, can be effectively used for preparation treatment perimenopausal syndrome medicine, and achieve non-through experiment
The most satisfied Advantageous Effects, relevant information is as follows:
1. materials and methods
1.1 experiment material
1.1.1 laboratory animal
SPF level mice, Kunming kind, female, 20-25g, Wuhan Biological Products Inst. provide.The quality certification is numbered:
42000400000611；Laboratory quality certification SYXK (Henan) 2010-001.
1.2 Experimental agents
Colla cornus cervi, Fructus Jujubae, stir-baked RHIZOMA DIOSCOREAE with soil, medical material company of Henan Province；Geng Nian An Capsules, Shanxi Tianxing Pharmaceutical Co., Ltd. is raw
Producing, ' soybean isoflavone dimension E soft capsule, Weihai Unisplendour Biotechnology Development Co., Ltd. produces lot number 121104, lot number
13070302。
1.3 experiment reagent
Sodium carboxymethyl cellulose, Tianjin star chemistry reagent Manufacturing Co., Ltd, lot number 20120418；Injection penicillium sp
Element sodium, North China pharmaceutical Co. Ltd produces, lot number c1206807；Formalin (analytical pure), Yantai City's limited public affairs of chemical industry in pairs
Department produces, lot number 20130902；0.9% sodium chloride injection, Cisen Pharmaceutical Co., Ltd. produces, lot number
1301265303；Chloral hydrate, Tianjin recovery fine chemistry industry institute, lot number 20120827；Mice E2ELISA detectable
Box, R&D company, lot number 20131001A；Mice T ELISA detection kit, R&D company, lot number 20131001A；Mice LH
ELISA detection kit, R&D company, lot number 20131001A；Mice FSH ELISA detection kit, R&D company, lot number
20131001A。
1.4 experimental apparatus
Electronic scale, Shanghai Minqiao Medical Apparatus and Instruments Co., Ltd., model JY601；Electronic analytical balance, Ao Haosi (Shanghai) is public
Department, model AR1140/C；High speed tabletop centrifuge, Anting Scientific Instrument Factory, Shanghai, model TGL-168；Electric-heated thermostatic water bath,
Shanghai Yiheng Scientific Instruments Co., Ltd, model HWS12；Mice autonomic activities tester, Chengdu TME Technology Co., Ltd., type
Number ZZ-6；Mice keeps away dark instrument, Chengdu TME Technology Co., Ltd., model BA-200；High speed refrigerated centrifuge, University of Science and Technology Innovations
Zhong Jia branch company of company limited, model KDC-160HR；Adjustable pipette, Shanghai Lei Bo Analytical Instrument Co., Ltd；Enzyme mark
Instrument, BIO-RAD company of the U.S., model: 680；Electric microscope, OLYMPUS company of Japan, model BX61.
1.2 experimental technique
1.2.1 modeling and administration
Modeling method: take body weight 23～25g female KM mice 100, takes 12 at random and is only used as outside blank group, do evil through another person
Art processes, and remaining mice makes climacteric model.After mouse weights pneumoretroperitoneum injects 10% chloral hydrate (0.03ml/10g) anesthesia
Abdomen position is fixed, then from mouse back most end rib, in midaxillary line and about 1cm infall cropping outside spinal column, after sterilization
Cutting skin and dorsal muscles about 0.5～1cm, the liparitosis that in the otch visual field, a visible milky is shinny, ovary i.e. embeds wherein.With
Pincet is clamped outside liparitosis pull-out otch gently, fractionation of fatty group, the most visible one thin-line-shaped irregular in yellowish red color
Ovary.First being ligatured by fallopian tube under ovary (including fat) fine rule during clip, then extract ovary, cornua uteri is put by postoperative taking advantage of a situation
Return in abdominal cavity, suture muscles and skin, extract bilateral ovaries with method.Careful postoperative is raised, intramuscular injection penicillin 200,000 u/kg
(every 0.1mL) is in case infecting, continuous 3d, every day 1 time.Start by only carrying out mouse vagina plate coating checking, every day 1 after operation 5d
Secondary, continuous 5d, to determine that ovary excises the most completely.Smear presents the mice emotionally reacted and is discarded, and selects 72 castrations
Mice is uniformly divided into 6 groups at random for experiment, respectively model group, Geng Nian An Capsules group, soybean isoflavone soft capsule completely
Group, large, medium and small dosage Colla cornus cervi granule group.
Dosage: 0.5%CMC compound method: weigh sodium carboxymethyl cellulose 4g, be made into 800ml with distilled water.Greatly,
In, low dose of Colla cornus cervi granule group dosage is respectively 1500mg/kg, 750mg/kg, 375mg/kg and (is administered volume 0.1ml/
10g).Collocation method: weigh Colla cornus cervi granule 15,7.5g, 3.75g respectively, first dissolve with a small amount of 0.5%CMC, the most fixed
Hold to 100ml, mix,.(675mg/kg, is made into 67.5mg/ml, 0.1ml/10g with distilled water to Geng Nian An Capsules, quite
In quantity 15 times)；Collocation method: take Geng Nian An Capsules 9, first dissolve with a small amount of 0.5%CMC, constant volume the most again
To 40ml, mixing, it is the dosage (675mg/kg) of Geng Nian An Capsules suspension.Soybean isoflavone dimension E soft capsule (250mg/
Kg, is made into 25mg/ml, 0.1ml/10g with distilled water, is equivalent to 15 times of quantity)；Collocation method: take soybean isoflavone
Capsule 2, first dissolves with a small amount of 0.5%CMC, and constant volume is to 40ml, mixing the most again, is soybean isoflavones capsules suspension
Dosage (250mg/kg).
Storage method: cold preservation, used time water proof warms.
Medication: each treated animal gives relative medicine on the 10th day in Post operation.Geng Nian An Capsules group gavages GENGNIANAN glue
Capsule suspension 675mg kg-1, soybean isoflavone soft capsule group gavages soybean isoflavone soft capsule suspension 250mg kg-1,
Large, medium and small dosage Colla cornus cervi grain fraction does not gavage large, medium and small dosage Colla cornus cervi granule 200mg kg by group-1、10mg·
kg-1、50mg·kg-1, 0.1ml/10g.Blank group and model group gavage same volume 0.5%CMC solution respectively, and every day, gavage was given
Medicine 1 time, successive administration 21d.
1.2.2 observation item and detection method
Each group mice measures autonomic activities number of times in 5min in time being administered 18 days, measures little mouse's head in time being administered 19-20 days
The number of times shocked by electricity in darkroom is entered in the incubation period in secondary entrance darkroom and 5min.2h (water 12h is can't help in fasting) after last is administered,
Pluck eyeball after mouse weights and take blood, separate serum, measure E in serum2, the content of T, LH, FSH；Then take off cervical vertebra and put to death mice,
Dissect mice, extract thymus, spleen, uterine cancer cell, weigh its weight in wet base and calculate organ index (organ index=internal organs weight in wet base
Mg/ Mouse Weight g), then takes hypophysis；Thymus, spleen, uterus, hypophysis are fixed in 10% formalin solution, paraffin bag
Burying, section, HE dyes, the tectology change that light Microscopic observation is respectively organized.
2.2.2.1 autonomic activities number of times is tested
Each group of mice is put in autonomic activities instrument, first adapts to environment 1min, then measure autonomic activities number of times in 5min.
2.2.2.2 darkness avoidance test test
Each group of mouse tail is put in determination box facing to the osculum entering darkroom, is trained, redeterminates little after 24h
Mus enters, in first entering into incubation period in darkroom and 5min, the number of times shocked by electricity in darkroom.
2.2.2.3 kit measurement method
The acquisition of serum specimen: use without pyrogen and endotoxic test tube, avoid any cytositimulation in operating process,
Collecting after blood, 3000 leave the heart 10 minutes by separation the most careful to serum and erythrocyte.
Mouse E2 (E2) ELISA detection kit assay method: take out from the aluminium foil bag after equilibrium at room temperature 20min
Required lath, residue lath puts back to 4 DEG C with from the sealing of seal bag.Arranging standard sample wells and sample aperture, standard sample wells respectively adds not
Standard substance 50 μ L with concentration.Sample aperture is initially charged sample to be tested 10 μ L, then adds Sample dilution 40 μ L (i.e. Sample Dilution 5
Times)；Blank well is not added with.In addition to blank well, in standard sample wells and sample aperture, every hole adds the detection of horseradish peroxidase-labeled
Antibody 100 μ L, seals reacting hole with shrouding film.37 DEG C of water-baths or calorstat incubation 60min.Discard liquid, absorbent paper arsis
Dry, cleaning mixture is filled it up with in every hole, stands 1min.Get rid of cleaning mixture, absorbent paper pats dry, so repeat to wash plate 5 times.Every hole is initially charged
The each 50 μ L of substrate A, B, 37 DEG C of lucifuges hatch 15min.Taking out ELISA Plate, every hole adds stop buffer 50 μ L, in 15min, at 450nm ripple
The long light absorption value (OD value) measuring each hole.Concentration according to standard substance and the OD value of correspondence, draw out standard substance regression curve, press
Curvilinear equation calculates each sample concentration value.Ultimate density is that practical measurement concentration is multiplied by extension rate.Wherein, standard substance (S0-
S5) concentration is followed successively by: 0,4,8,16,32,64pmol/L.
Mice (Mouse) testosterone (T) ELISA detection kit standard substance (S0-55) concentration is followed successively by: 0,50,100,
200、400、800pg/mL；
Mice (Mouse) lutropin (LH) ELISA detection kit standard substance (S0-55) concentration is followed successively by: 0,
0.5、1、2、4、8mIU/mL；
0,5 mice (Mouse) follicle stimulating hormone (FSH) ELISA detection kit standard substance (S0-55) concentration is followed successively by:,
10、20、40、80mIU/mL。
2.3 statistical procedures methods
Data analysis SPSS17.0 medical statistics bag carries out the statistical procedures of data information, measurement data average
± standard deviationRepresenting, comparing employing one factor analysis of variance between each group, the neat person of variance test uses LSD method, heterogeneity of variance
Person checks by Games-Howel l method, and ranked data use Ridit inspection.
2. result
1 impact on mice climacteric model autonomic activities
Test each group of mice autonomic activities test result, be shown in Table 1.
The impact on climacteric model mice autonomic activities of the table 1 Colla cornus cervi granule
Note: compare with model group, * P < 0.05, * * P < 0.01
As seen from the above table, and blank group ratio, the movable number of times of model group mice, number of times of standing all substantially reduce (P <
0.01), illustrate that the curious degree of fresh ambient is reduced by climacteric model mice.With model group ratio, soybean isoflavone flexible glue
Capsule, Geng Nian An Capsules, big or middle dosage Colla cornus cervi granule group be all remarkably improved the movable number of times of mice and number of times of standing (P <
0.01), low dose of Colla cornus cervi granule group can significantly improve the movable number of times of mice and number of times (P < 0.05) of standing.
2 on mice climacteric model step-through test incubation period and the impact that is electrically shocked number of times
Test each group of mice step-through test test result, be shown in Table 2.
Table 2 Colla cornus cervi Granules on Mouse climacteric model step-through test incubation period and the impact of number of shocks
Note: compare with model group, * P < 0.05, * * P < 0.01
As seen from Table 2, and blank group ratio, the incubation period of model group mice, number of shocks all substantially reduce (P < 0.01),
Reflect mice climacteric model hypomnesis.With model group ratio, Geng Nian An Capsules, soybean isoflavone soft capsule, big or middle
Dosage Colla cornus cervi granule is all remarkably improved the incubation period of the step-through test of mice, reduces number of shocks (P < 0.01), improves little
Mus memory；Low dose of Colla cornus cervi granule can obviously reduce number of shocks (P < 0.05).
3 impacts on mice climacteric model organ index
Test each group of mouse thymus, spleen, uterus index, be shown in Table 3.
Table 3 Colla cornus cervi Granules on Mouse climacteric model thymus, spleen, the impact of uterus index
Note: compare with model group, * P < 0.05, * * P < 0.01
As can be seen from Table 3, with blank group ratio, the uterus index of model group mice significantly reduces (P < 0.01), and explanation is plucked
Except ovary causes climacteric model mice metratrophia, extract ovary thus estrogen secretion deficiency causes climacteric mice
Atrophy of immune organ.With model group ratio, soybean isoflavone soft capsule, Geng Nian An Capsules, big or middle dosage Colla cornus cervi granule all can show
Write and improve thymus, spleen, uterus index (P < 0.01).
4 impacts on mice climacteric model serum sex hormone level
E in each group mice serum2, T, FSH, LH content.It is shown in Table 4～5.
E in table 4 Colla cornus cervi Granules on Mouse climacteric model serum2, the impact of T level
Note: compare with model group, * P < 0.05, * * P < 0.01
Table 5 locks capsule to the impact of FSH, LH level in mice climacteric model serum
Note: compare with model group, * P < 0.05, * * P < 0.01
From table 4～5 it can be seen that with blank group ratio, in model group mice serum, E2, T level is remarkably decreased (P < 0.01),
LH, FSH level significantly raises (P < 0.01), illustrates that extracing ovary causes the gonadal hormone water in climacteric model mice serum
Flat disorder, climacteric mouse model replicates successfully.Dosage Colla cornus cervi granule big or middle and Geng Nian An Capsules, soybean isoflavone are soft
Capsule can significantly raise E2, T level (P < 0.01) in mice climacteric model serum and reduce FSH, the LH raised in serum
Level.Low dose of Colla cornus cervi granule can obviously reduce the FSH level in serum and T level (P < 0.05).
5. the impact on climacteric model mice organ-tissue form
Test each group of Mouse Uterus, thymus, spleen, hypophysis pathologic examination result as follows, pathological photograph is shown in attached
Climacteric type mice pathological photograph in record 1.
5.1 impacts on climacteric model mice uterus histomorphology
The change in various degree occurred according to each group of endometrium of mouse of experiment, body of gland, muscle layer, uses sxemiquantitative mark
Standard, is divided into four ranks by Pathomorphologic, is measured each group of Mouse Uterus of experiment, and observed result is shown in Table 7.
Table 7 Colla cornus cervi granule affects unit to the uterus pathological change of climacteric model mice: only
"-" endometrial epithelial cell, body of gland, muscle layer, serous coat are the most normal；The few portion of "+" endometrial epithelial cell, body of gland
Dividing atrophy, muscle layer serous coat is the most normal；" ++ " endometrial epithelial cell, body of gland part atrophy, muscle layer slightly atrophy, serous coat is just
Often；The obvious atrophy of " +++ " endometrial epithelial cell, body of gland, serous coat is normal.
Checking through Ridit, as can be known from the above table, with blank group ratio, model group Mouse Uterus occurs that significant pathological tissue is sick
Become (P < 0.01).With model group ratio, soybean isoflavone ties up E soft capsule, Geng Nian An Capsules, middle dosage Colla cornus cervi granule all can be notable
The uterus pathology lesion tissue (P < 0.01) improving mice, heavy dose of Colla cornus cervi granule can significantly improve the hysteropathy of mice
Reason lesion tissue (P < 0.05).
5.2 on mice climacteric model thymus, the impact of spleen tissue form
Use micrometer, each group every Mouse Thymic Cortex thickness of experiment and the narrowest place are measured its thickness and try to achieve all
Number；The baseline using micrometer falls on splenic nodule, measures the splenic nodule thickness size of both sides centered by central artery respectively,
Seek mean；The results are shown in Table 8.
Table 8 locks capsule to climacteric model mice thymus, the impact of spleen pathological change
Note: compare with model group, * P < 0.05, * * P < 0.01
As can be seen from Table 7, and blank group ratio, model group Mouse Thymic Cortex thickness, splenic nodule volume substantially reduce (P <
0.01), illustrate that mice makes thymus, spleen volume atrophy after climacteric model.With model group ratio, heavy dose of Colla cornus cervi granule can
Significantly thickening thymic cortex thickness and splenic nodule volume (P < 0.01), it is thick that middle dosage Colla cornus cervi granule can substantially thicken thymic cortex
Degree (P < 0.05).
5.3 impacts on mice climacteric model pituitary tissue form
It is 10000 μm that high power field falls at area2Basophil quantity and gene expression in micrometer rectangle frame
Quantity.The results are shown in Table 9.
The impact on climacteric model mice hypophysis pathological change of the table 9 Colla cornus cervi granule
Note: compare with model group, * P < 0.05, * * P < 0.01
As can be seen from Table 8, with blank group ratio, model group basophil quantity and gene expression quantity significantly drop
Low (P < 0.01), after illustrating that mice makes climacteric model, the cell source of secretion promoting sexual gland hormone reduces.With model group ratio, big,
Middle dosage Colla cornus cervi granule group can dramatically increase basophilic cell quantity and gene expression quantity (P < 0.01).
3. conclusion
Fully show that by above-mentioned experiment the improvement result that Colla cornus cervi Granules on Mouse climacteric model has had significantly carries
The movable number of times of high mice and number of times of standing, significantly improve the incubation period of the step-through test of mice, reduces number of shocks, improves little
Mus memory, can significantly raise E2, T level in mice climacteric model serum and reduce FSH, LH water raised in serum
Flat, the uterus pathology lesion tissue of mice can be significantly improved, can significantly thicken thymic cortex thickness and splenic nodule volume, group can show
Write and increase basophilic cell quantity and gene expression quantity, be effective to the medicine of preparation treatment perimenopausal syndrome
Thing, is the innovation on treatment perimenopausal syndrome medicine, has the using value of reality.
Claims (5)
1. a Colla cornus cervi granule, it is characterised in that be made up of Colla cornus cervi 18-22g, stir-baked RHIZOMA DIOSCOREAE with soil 9-11g, Fructus Jujubae 9-11g, its
In, Fructus Jujubae, every time with the soak by water 2 times of Fructus Jujubae weight 6-8 times, decocts 30-40 minute every time, merges twice decocting liquid, be concentrated into phase
When in containing crude drug 2g/ml, obtain Fructus Jujubae water drug-decocting concentrating liquid；After Colla cornus cervi molten, it is dissolved in Fructus Jujubae water drug-decocting concentrating liquid, obtains mixing
Liquid；Stir-baked RHIZOMA DIOSCOREAE with soil was ground into the fine powder of 100 mesh sieves again, dissolved in mixed liquor, decompression drying, it was ground into 100 mesh sieves
Fine powder, with the ethanol mixed pelletization of mass concentration 90%, dries, obtains Colla cornus cervi granule.
Colla cornus cervi granule the most according to claim 1, it is characterised in that by Colla cornus cervi 20g, stir-baked RHIZOMA DIOSCOREAE with soil 10g, Fructus Jujubae
10g makes, wherein, Fructus Jujubae boiling 2 times, add the water of Fructus Jujubae weight 8 times for the first time, decoct 40 minutes, filter, obtain first
Secondary filtrate, medicinal residues, again with the water of Fructus Jujubae weight 6 times, decoct 30 minutes, filter, and obtain second time filtrate, merge twice filtrate, concentrate
To being equivalent to containing crude drug 2g/ml, obtain Fructus Jujubae water drug-decocting concentrating liquid；After Colla cornus cervi molten, it is dissolved in Fructus Jujubae water drug-decocting concentrating liquid, obtains mixed
Close liquid；Stir-baked RHIZOMA DIOSCOREAE with soil was ground into the fine powder of 100 mesh sieves again, dissolved in mixed liquor, decompression drying, it was ground into 100 mesh sieves
Fine powder, with the ethanol mixed pelletization of mass concentration 90%, dry, obtain Colla cornus cervi granule.
Colla cornus cervi granule the most according to claim 1, it is characterised in that by Colla cornus cervi 19g, stir-baked RHIZOMA DIOSCOREAE with soil 10.5g, Fructus Jujubae
9.5g make.
Colla cornus cervi granule the most according to claim 1, it is characterised in that by Colla cornus cervi 21g, stir-baked RHIZOMA DIOSCOREAE with soil 9.5g, Fructus Jujubae
10.5g makes.
5. the answering in preparation treatment perimenopausal syndrome medicine of the Colla cornus cervi granule described in any one of claim 1 or 2-4
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401817.9A CN105832960A (en) | 2016-06-08 | 2016-06-08 | Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401817.9A CN105832960A (en) | 2016-06-08 | 2016-06-08 | Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105832960A true CN105832960A (en) | 2016-08-10 |
Family
ID=56576594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610401817.9A Pending CN105832960A (en) | 2016-06-08 | 2016-06-08 | Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105832960A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106334063A (en) * | 2016-09-21 | 2017-01-18 | 河南中医药大学 | Cornu cervi pantotrichum powder for treating perimenopausal syndrome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814119A (en) * | 2005-11-22 | 2006-08-09 | 江西银涛药业有限公司 | Yougui capsule |
-
2016
- 2016-06-08 CN CN201610401817.9A patent/CN105832960A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814119A (en) * | 2005-11-22 | 2006-08-09 | 江西银涛药业有限公司 | Yougui capsule |
Non-Patent Citations (2)
| Title |
|---|
| 吕桂华: "更年期妇女保健及中医中药防治", 《青岛医药卫生》 * |
| 王彭龄: "《中西医结合防止老年泌尿生殖系统疾病》", 31 August 2007, 吉林科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106334063A (en) * | 2016-09-21 | 2017-01-18 | 河南中医药大学 | Cornu cervi pantotrichum powder for treating perimenopausal syndrome |
| CN106334063B (en) * | 2016-09-21 | 2019-06-18 | 河南中医药大学 | A kind of pilose antler powder for treating perimenopausal syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083473A (en) | Application of raspberry extract in preparation of drug for treating perimenopausal syndrome | |
| CN101850016B (en) | Chinese medicinal composition for treating premature ovarian failure and preparation method thereof | |
| Tian et al. | Study on neuroendocrine-immune function of Phenylethanoid Glycosides of Desertliving Cistanche herb in perimenopausal rat model | |
| CN1275639C (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN103830577A (en) | Medicine composition for treating liver and gall calculus and kidney stone and application thereof | |
| CN105998276A (en) | Application of total flavones of oldenlandia diffusa willd in preparing drugs for treating meningeal microcirculation disturbance and cerebral ischemia by serving as only active site | |
| CN102258549A (en) | New application of cynomorium songaricum extract in preparing medicines for treating female climacteric syndrome | |
| CN102266415B (en) | Application of compound traditional Chinese medicine in prevention and treatment of osteoporosis disease | |
| CN103690782A (en) | Traditional Chinese medicine composition for treating climacteric syndrome, and preparation method and quality detection method thereof | |
| CN105832960A (en) | Application of deer-horn glue particles in preparing drug for treating perimenopausal syndrome | |
| CN106309543A (en) | Application of psoralen total flavonoid in preparation of medicaments for treating perimenopausal syndromes | |
| CN106236799A (en) | The application in preparation treatment perimenopausal syndrome medicine of the Fructus Cnidii total flavones | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN103041306B (en) | Traditional Chinese medicine composition for curing climacteric syndrome of women and preparation method thereof | |
| CN103272119A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN106138955A (en) | The application in exhausted premenstrual syndrome medicine is treated in preparation of the Fructus Alpiniae Oxyphyllae total flavones | |
| CN106420945A (en) | Application of cistanche phenylethanoid glycoside in preparation of medicine for treating perimenopausal syndrome | |
| CN104096089B (en) | Traditional Chinese medicine composition for treating ischemia apoplexy, and capsules and preparation method thereof | |
| CN106075007A (en) | The application in preparation treatment study on perimenopausal depressive disorder medicine of the leek seed total flavone | |
| CN105943591A (en) | Application of fenugreek total flavones to preparation of medicine for treating perimenopausal syndromes | |
| CN106420891A (en) | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome | |
| CN109010418A (en) | A kind of method and application for extracting fenugreek extract from faenum graecum | |
| CN104587140A (en) | New application of hellebore estrogen receptor antagonist | |
| CN110141634A (en) | A kind of qi-regulating dissipating bind particle and preparation method thereof | |
| Shan et al. | Effects of Curculigo orchioides total glucosides in mouse perimenopause model of related organization and organs morphology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |
|
| RJ01 | Rejection of invention patent application after publication |